Evidence map›Paper›PMID 24918007›Full record

ArticleUnited European gastroenterology journal2014

Clinical and genetic factors predicting response to therapy in patients with Crohn's disease.

Marilia Cravo, Paula Ferreira, Patricia Sousa, Paula Moura-Santos, Sonia Velho, Lurdes Tavares, João Ramos Deus, Paula Ministro, João Pereira da Silva, Luis Correia and 3 more

Abstract read
In one paragraph

Article in United European gastroenterology journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. The role of FAS gene variants in inflammatory bowel disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marilia CravoHospital Beatriz Angelo, Loures, Portugal ; Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.
Paula FerreiraEscola Superior de Tecnologias da Saude, Lisbon, Portugal.
Patricia SousaHospital Santa Maria, Lisboa, Portugal.
Paula Moura-SantosFaculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal ; Hospital Santa Maria, Lisboa, Portugal.
Sonia VelhoHospital Beatriz Angelo, Loures, Portugal.
Lurdes TavaresHospital Santa Maria, Lisboa, Portugal.
João Ramos DeusHospital Fernando da Fonseca, Amadora, Portugal.
Paula MinistroHospital S Teotónio, Viseu, Portugal.
João Pereira da SilvaInstituto Portugués de Oncologia, Lisboa, Portugal.
Luis CorreiaFaculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal ; Hospital Santa Maria, Lisboa, Portugal.
Jose VelosaFaculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal ; Hospital Santa Maria, Lisboa, Portugal.
Rui MaioHospital Beatriz Angelo, Loures, Portugal.
Miguel BritoEscola Superior de Tecnologias da Saude, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo identify clinical and/or genetic predictors of response to several therapies in Crohn's disease (CD) patients.

methodsWe included 242 patients with CD (133 females) aged (mean ± standard deviation) 39 ± 12 years and a disease duration of 12 ± 8 years. The single-nucleotide polymorphisms (SNPs) studied were ABCB1 C3435T and G2677T/A, IL23R G1142A, C2370A, and G9T, CASP9 C93T, Fas G670A and LgC844T, and ATG16L1 A898G. Genotyping was performed with real-time PCR with Taqman probes.

resultsOlder patients responded better to 5-aminosalicylic acid (5-ASA) and to azathioprine (OR 1.07, p = 0.003 and OR 1.03, p = 0.01, respectively) while younger ones responded better to biologicals (OR 0.95, p = 0.06). Previous surgery negatively influenced response to 5-ASA compounds (OR 0.25, p = 0.05), but favoured response to azathioprine (OR 2.1, p = 0.04). In respect to genetic predictors, we observed that heterozygotes for ATGL16L1 SNP had a significantly higher chance of responding to corticosteroids (OR 2.51, p = 0.04), while homozygotes for Casp9 C93T SNP had a lower chance of responding both to corticosteroids and to azathioprine (OR 0.23, p = 0.03 and OR 0.08, p = 0.02,). TT carriers of ABCB1 C3435T SNP had a higher chance of responding to azathioprine (OR 2.38, p = 0.01), while carriers of ABCB1 G2677T/A SNP, as well as responding better to azathioprine (OR 1.89, p = 0.07), had a lower chance of responding to biologicals (OR 0.31, p = 0.07), which became significant after adjusting for gender (OR 0.75, p = 0.005).

conclusionsIn the present study, we were able to identify a number of clinical and genetic predictors of response to several therapies which may become of potential utility in clinical practice. These are preliminary results that need to be replicated in future pharmacogenomic studies.

Indexed as

clinical genetic predictorsCrohn’s diseaseresponse to therapy

Identifiers

PMID24918007
PMCPMC4040806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.